Ralph E Parchment

20120093718, Apr 19, 2012

Mar 29, 2007

12/301587

Ralph E. Parchment - Hagerstown MD, US
Bhaskara R. Jasti - Stockton CA, US
Ramesh R. Boinpally - Broomfield CO, US
Stephen E. Rose - Flushing MI, US
Earle T. Holsapple - Grosse Pointe Farms MI, US

SCITECH DEVELOPMENT, LLC - Grosse Pointe Farms MI
WAYNE STATE UNIVERSITY - Detroit MI

A61K 9/14
A61P 35/00
A61P 1/18
A61K 49/18
A61K 49/00
B29B 9/04
A61K 31/167
A61K 51/12
B82Y 5/00

424 129, 424502, 514613, 424 93, 424 96, 264 9, 977797, 977773, 977906

Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.

20200292537, Sep 17, 2020

Mar 16, 2017

16/085999

- Rockville MD, US
Thomas D. Pfister - Rockville MD, US
Tony Navas - Rockville MD, US
Ralph E. Parchment - Rockville MD, US
James E. Doroshow - Rockville MD, US

THEUNITEDSTATES OF AMERICA ASREPRESENTEDBYTHE SECRETARYOF THEDEPARMENT OF HEALTH AND HUMAN SERVICE - Rockbille MD

G01N 33/543
C12N 15/63
C07K 16/44

Methods and compositions are described herein for assaying the presence or absence of pY1235-MET or a fragment thereof.

20160251447, Sep 1, 2016

Oct 8, 2014

15/027997

- Bethesda MD, US
Allison M. Marrero - Gaithersburg MD, US
Ralph E. Parchment - Hagerstown MD, US
James H. Doroshow - Bethesda MD, US

THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human... - Bethesda MD

C07K 16/40
G01N 33/573

Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.